PROFILPELAJAR.COM

E2511

E2511
Clinical data
Other namesE-2511
Routes of
administration		Oral[1]
Drug classTropomyosin receptor kinase A (TrkA) positive allosteric modulator
Pharmacokinetic data
Elimination half-life3.2 hours[2][3][4]

E2511, or E-2511, is a selective biased tropomyosin receptor kinase A (TrkA) positive allosteric modulator which is under development for the treatment of Alzheimer's disease.[1][2][3][5][6] It is taken orally.[1] The drug has been found to increase cholinergic signaling in preclinical research.[2][3][7][8] The elimination half-life of E2511 is 3.2 hours in humans.[2][3][4] E2511 is under development by Eisai.[1][2] As of September 2024, it is in phase 1 clinical trials for Alzheimer's disease.[1][2] A phase 1 clinical trial has been completed.[1][2][4] The chemical structure of E2511 does not yet appear to have been disclosed.[1][3]

See also

References

  1. ^ a b c d e f g "E 2511". AdisInsight. 26 September 2024. Retrieved 10 June 2026.
  2. ^ a b c d e f g "E2511". ALZFORUM. 9 November 2023. Retrieved 10 June 2026.
  3. ^ a b c d e Forsell P, Parrado Fernández C, Nilsson B, Sandin J, Nordvall G, Segerdahl M (July 2024). "Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer's Disease". Pharmaceuticals. 17 (8). Basel, Switzerland: 997. doi:10.3390/ph17080997. PMC 11357672. PMID 39204102.
  4. ^ a b c Aceves P, Hall N, Dayal S, Yagi T, Chang J, Mikamoto M, et al. (2023). "First-in-Human (FIH), Single- and Multiple-Ascending-Dose (SAD/MAD) studies in healthy subjects of E2511, a novel tropomyosin receptor kinase a (TrkA) positive allosteric modulator (PAM)". Alzheimer's & Dementia. 19 (S7) e066208. doi:10.1002/alz.066208. ISSN 1552-5260.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  5. ^ Enkavi G (February 2026). "Molecular determinants of signal transduction in tropomyosin receptor kinases". FEBS Open Bio. 16 (2): 252–267. doi:10.1002/2211-5463.70135. PMC 12871558. PMID 41053984.
  6. ^ Nordvall G, Forsell P, Sandin J (October 2022). "Neurotrophin-targeted therapeutics: A gateway to cognition and more?". Drug Discovery Today. 27 (10) 103318. doi:10.1016/j.drudis.2022.07.003. PMID 35850433.
  7. ^ Tomioka T, Hiramatsu N, Moriyama Y, Kosasa T (2023). "E2511, a novel small compound TrkA biased positive allosteric modulator, reinnervates cholinergic neuron and activates cholinergic functions in non-clinical studies". Alzheimer's & Dementia. 19 (S7) e062590. doi:10.1002/alz.062590. ISSN 1552-5260.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  8. ^ Tomioka T, Moriyama Y, Hiramatsu N, Kosasa T, Kondo K, Wakita H (2021). "E2511, a novel small compound TrkA allosteric modulator, induces a specific trophic signaling via direct binding to TrkA, and can reverse the loss of choline acetyltransferase (ChAT) positive neurons in transgenic models of AD". Alzheimer's & Dementia. 17 (S9) e051985. doi:10.1002/alz.051985. ISSN 1552-5260.{{cite journal}}: CS1 maint: unflagged free DOI (link)
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.